Medline (NASDAQ:MDLN) Raised to “Moderate Buy” at Royal Bank Of Canada

Medline (NASDAQ:MDLN) was upgraded by equities researchers at Royal Bank Of Canada to a “moderate buy” rating in a research note issued on Monday,Zacks.com reports.

Other analysts also recently issued reports about the stock. Morgan Stanley started coverage on shares of Medline in a report on Sunday. They issued an “overweight” rating and a $48.00 target price on the stock. JPMorgan Chase & Co. assumed coverage on Medline in a research note on Monday. They set an “overweight” rating and a $50.00 price objective on the stock. Wolfe Research started coverage on Medline in a research report on Monday. They set an “outperform” rating and a $47.00 price objective on the stock. The Goldman Sachs Group started coverage on Medline in a report on Monday. They issued a “buy” rating and a $49.00 target price for the company. Finally, William Blair started coverage on Medline in a report on Monday. They set an “outperform” rating on the stock. Eight research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $46.70.

Medline Price Performance

NASDAQ MDLN opened at $42.72 on Monday. Medline has a one year low of $34.89 and a one year high of $45.50.

Insider Transactions at Medline

In other Medline news, Director Charles N. Mills purchased 2,579,310 shares of the firm’s stock in a transaction that occurred on Thursday, December 18th. The stock was purchased at an average cost of $29.00 per share, with a total value of $74,799,990.00. Following the purchase, the director owned 2,441,379 shares of the company’s stock, valued at approximately $70,799,991. The trade was a -1,870.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Andrew J. Mills acquired 2,586,206 shares of the company’s stock in a transaction that occurred on Thursday, December 18th. The shares were acquired at an average price of $29.00 per share, with a total value of $74,999,974.00. Following the acquisition, the director owned 2,586,206 shares in the company, valued at $74,999,974. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.

Trending Headlines about Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Numerous analysts initiated buy/overweight ratings (Barclays, Jefferies, Bank of America, JPMorgan, Wolfe, Mizuho, TD Cowen, Stifel, Piper Sandler, Bernstein, J.P. Morgan, William Blair, Robert W. Baird, Truist). Several targets sit in the $46–$52 range, implying notable upside and helping fuel buying interest. Medline Stock Surges on Post‑IPO Buy Notes
• Positive Sentiment: Jefferies highlighted Medline’s $25 billion supply‑chain scale and gave a “buy” in its coverage debut — a validation of the company’s scale and margin expansion thesis that investors favor. Jefferies Coverage
• Positive Sentiment: Benzinga and other outlets note Medline raised ~$7 billion in its IPO and is being praised for a “prime vendor” model, branded mix shift and margin expansion potential — fundamental reasons analysts cite for buy ratings. Analysts Say Medline Has The Secret Sauce
• Neutral Sentiment: Valuation checks and commentary: several writeups assess MDLN near discounted cash‑flow estimates or “fairly priced” after the recent stability — these limit runaway upside and suggest gains are tied to multiple expansion as much as earnings. Valuation Check
• Neutral Sentiment: Short interest report in the period shows effectively zero/ambiguous data (odd reporting numbers). No clear short‑squeeze signal — treat short‑interest data as non‑contributory for now.
• Negative Sentiment: Some shops initiated neutral/hold ratings with lower targets (BNP Paribas $38 target, Deutsche Bank $40, Wells Fargo $42, Rothschild $42). Those lower targets cap consensus upside and could pressure the stock if follow‑through selling emerges.

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.